Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
19 mai 2023 06h15 HE
|
Liquidia Corporation
MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use...
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
04 mai 2023 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The...
Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference
02 mai 2023 06h45 HE
|
Liquidia Corporation
MORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an update on the company's...
Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023
27 avr. 2023 06h45 HE
|
Liquidia Corporation
MORRISVILLE, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The...
Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 06h45 HE
|
Liquidia Corporation
MORRISVILLE, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an overview and update on the...
Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications
03 avr. 2023 06h45 HE
|
Liquidia Corporation
New agreement supersedes the collaboration agreement entered in 2012GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled deliveryLiquidia can apply PRINT to any inhaled...
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update
16 mars 2023 06h30 HE
|
Liquidia Corporation
Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host webcast today at 8:30 a.m. ET ...
Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023
09 mars 2023 07h19 HE
|
Liquidia Corporation
MORRISVILLE, N.C., March 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2022 financial results on Thursday, March 16, 2023. The...
Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
02 févr. 2023 16h39 HE
|
Liquidia Corporation
PTAB rejects UTHR’s request for rehearing of its decision in the inter partes review of the ‘793 Patent (‘793 IPR)PTAB clarified grounds upon which it based its finding that the cited publications,...
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02 févr. 2023 06h30 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of...